<?xml version="1.0" encoding="UTF-8"?>
<p id="p0185">The suitable medications for COVID-19 are still under search. So far, one of the most promising drugs is remdesivir (GS-5734), produced by Gilead Science, a nucleoside analog that mimics adenosine for previously treatment of the Ebola virus infection [
 <xref rid="bib110" ref-type="bibr">110</xref>]. Health authorities in China have initiated clinical trials at multiple places in Hubei province to evaluate the safety and efficacy of remdesivir on patients. However, under the pandemic emergencies, the patients who recovered from critical situation usually took multiple medications rather than remdesivir, which made assessment of the data from clinical trials somewhat complicated [
 <xref rid="bib111" ref-type="bibr">111</xref>]. Besides of China, Gilead Science started phase III trial. National Institute of Allergy and Infectious Diseases (NIAID) in the US are conducting phase II trial. The French National Institute of Health and Medical Research (INSERM) also evaluated the effect of remdesivir and other treatment on COVID-19 patients [
 <xref rid="bib112" ref-type="bibr">112</xref>].
</p>
